Medmix Forecast, price target & analysts
Medmix Target price 2026 - Analyst rating & recommendation
Medmix Classifications & Recommendation:
Medmix Price Target
| Target Price | CHF18.36 |
| Price | CHF11.24 |
| Potential |
63.35%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Medmix 2027 .
The average Medmix target price is CHF18.36.
This is
63.35%
register free of charge
CHF21.00
86.83%
register free of charge
CHF14.65
30.29%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Medmix to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medmix stock has an average upside potential 2027 of
63.35%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 483.90 | 475.03 |
| 0.55% | 1.83% | |
| EBITDA Margin | 16.62% | 17.67% |
| 10.15% | 6.35% | |
| Net Margin | -1.53% | 3.04% |
| 2,580.43% | 298.79% |
4 Analysts have issued a sales forecast Medmix 2025 . The average Medmix sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Medmix EBITDA forecast 2025. The average Medmix EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Medmix Analysts have issued a net profit forecast 2025. The average Medmix net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | -0.18 | 0.35 |
| 1,900.00% | 294.44% | |
| P/E | 31.80 | |
| EV/Sales | 1.42 |
4 Analysts have issued a Medmix forecast for earnings per share. The average Medmix EPS is
This results in the following potential growth metrics and future valuations:
Current Medmix Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Nov 25 2025 |
| RESEARCH PARTNERS AG |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Nov 25 2025 |
|
Locked
RESEARCH PARTNERS AG:
Locked
➜
Locked
|
Feb 26 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
